Extract
According to the international consensus statement of 2011, idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP) are classified as fibrotic idiopathic interstitial pneumonia (f-IIP) of unknown aetiology [1]. f-IIP patients display persistent and significant dyspnoea, exercise intolerance and poor health-related quality of life [2]. f-IIP is also associated with a marked reduction in daily life physical activity (DLPA) [3], which is related to morbidity and mortality in many chronic diseases, including f-IIP [4–6].
Abstract
Fibrotic idiopathic interstitial pneumonia patients derived benefit from a pulmonary rehabilitation programme in terms of exercise tolerance, anxiety, depression and quality of life without increasing their daily life physical activity http://ow.ly/WV7U30kgNkU
Footnotes
Author contributions: Conception, design, data analysis and interpretation: B. Wallaert, N. Masson, L. Wémeau-Stervinou and J.M. Grosbois; drafting of the manuscript for important intellectual content: B. Wallaert, N. Masson, O. Le Rouzic, B. Chéhère, L. Wémeau-Stervinou, and J.M. Grosbois.
Conflict of interest: B. Wallaert reports personal fees, non-financial support and other (advisory board) from Boehringer Ingelheim, personal fees and non-financial support from Vitalaire, personal fees, non-financial support and other (advisory board) from Roche, outside the submitted work.
Conflict of interest: O. Le Rouzic reports personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, Chiesi, Lilly and Novartis; non-financial support from GlaxoSmithKline, MundiPharma, Pfizer, Teva, Santelys Association, Vertex and Vitalaire, all outside the submitted work.
Conflict of interest: L. Wémeau-Stervinou reports personal fees, non-financial support and other (advisory board) from Boehringer-Ingelheim, personal fees and non-financial support from Roche, personal fees from Bristol-Myers-Squibb and Janssen-Cilag, outside the submitted work.
Conflict of interest: Formaction Santé (J.M. Grosbois) received financial support from Adair, France Oxygène, Homeperf, LVL, Orkyn, Santélys, SOS Oxygène, Sysmed, VitalAire, and the ARS Hauts-de-France for home-based PR programmes.
- Received December 19, 2017.
- Accepted May 12, 2018.
- Copyright ©ERS 2018
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.